<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DOPRAM- doxapram hydrochlorideÂ injectionÂ </strong><br>West-ward Pharmaceutical Corp.<br></p></div>
<h1>DOPRAM Injection<br>(doxapram hydrochloride injection, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_791b0f49-4005-4449-9a99-6006406a7eee"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">NOT FOR USE IN NEONATES<br></span><span class="Bold">CONTAINS BENZYL ALCOHOL<br></span><span class="Bold">Rx only</span>Â </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_92855bbc-ea46-4a77-9634-abb1d91c7484"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DOPRAM Injection (doxapram hydrochloride injection, USP) is a clear, colorless, sterile, non-pyrogenic, aqueous solution with pH 3.5 to 5, for intravenous administration.</p>
<p>Each 1 mL contains:</p>
<p>Doxapram Hydrochloride, USP ................................................................. 20 mg<br>Benzyl Alcohol, NF (as preservative) ......................................................... 0.9%<br>Water for Injection, USP ...........â€¦................................................................. q.s.</p>
<p>Doxapram Injection is a respiratory stimulant.</p>
<p>Doxapram hydrochloride is a white to off-white, crystalline powder, sparingly soluble in water, alcohol and chloroform. Chemically, doxapram hydrochloride is 1-ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-2-pyrrolidinone monohydrochloride, monohydrate.</p>
<p>The chemical structure is:</p>
<div class="Figure">
<img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb&amp;name=dopram-1.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>C<span class="Sub">24</span>H<span class="Sub">31</span>ClN<span class="Sub">2</span>O<span class="Sub">2</span> â€¢ H<span class="Sub">2</span>OÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â M.W. 432.98</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_13110994-45a3-49bc-8343-9d4f2343544d"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_13566dc3-9f7a-4988-bb52-16201bc5207a"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Doxapram hydrochloride produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. As the dosage level is increased, the central respiratory centers in the medulla are stimulated with progressive stimulation of other parts of the brain and spinal cord.</p>
<p>The onset of respiratory stimulation following the recommended single intravenous injection of doxapram hydrochloride usually occurs in 20 to 40Â seconds with peak effect at 1 to 2Â minutes. The duration of effect may vary from 5 to 12Â minutes.</p>
<p>The respiratory stimulant action is manifested by an increase in tidal volume associated with a slight increase in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>.</p>
<p>A pressor response may result following doxapram administration. Provided there is no impairment of cardiac function, the pressor effect is more marked in hypovolemic than in normovolemic states. The pressor response is due to the improved <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> rather than <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">peripheral vasoconstriction</span>. Following doxapram administration, an increased release of catecholamines has been noted.</p>
<p>Although opiate-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> is antagonized by doxapram, the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> is not affected.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_3e9932cb-bead-4697-b53d-a5e7907acfb8"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Doxapram is metabolized via ring hydroxylation to ketodoxapram, an active metabolite readily detected in the plasma.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_fb3c6546-26c1-4bf5-9cb5-d23cc423bd27"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_464016e8-e55b-4779-9cac-46d8519a7f25"></a><a name="section-4.1"></a><p></p>
<h2>Postanesthesia</h2>
<ol class="LittleAlpha">
<li>When the possibility of airway obstruction and/or <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> other than that due to muscle relaxant drugs.
</li>
<li>To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.)</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d6cbe469-15f6-4b34-b45a-926197c6556b"></a><a name="section-4.2"></a><p></p>
<h2>Drug-Induced Central Nervous System <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">Exercising care to prevent <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> due to drug overdosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_672fd84c-9605-4485-81e4-44fff86d7bdd"></a><a name="section-4.3"></a><p></p>
<h2>Chronic Pulmonary Disease Associated with Acute <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">Hypercapnia</span></h2>
<p class="First">Doxapram is indicated as a temporary measure in hospitalized patients with acute <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span> superimposed on <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>. Its use should be for a short period of time (see <span class="Bold"><a href="#LINK_e82b2ef3-3390-46d6-a7f6-7bcb87069953">DOSAGE AND ADMINISTRATION</a></span>) as an aid in the prevention of elevation of arterial CO<span class="Sub">2</span> <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> during the administration of oxygen.</p>
<p>It should not be used in conjunction with mechanical ventilation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_0c7e3632-c211-41d1-aa40-030c23f57c57"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Doxapram is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or any of the injection components.</p>
<p>Doxapram should not be used in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>.</p>
<p>Doxapram is contraindicated in patients with proven or suspected <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p>Doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction, muscle <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span> (including <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>), flail chest, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, acute bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, or other conditions resulting in restriction of the chest wall, muscles of respiration, or alveolar expansion.</p>
<p>Doxapram is contraindicated in patients with evidence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, or <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, and in those with significant cardiovascular impairment, uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, severe <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, or severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, including that associated with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. (See <span class="Bold"><a href="#LINK_b04a2a24-6d60-41fd-b801-2813cbb40852">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_b04a2a24-6d60-41fd-b801-2813cbb40852"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Doxapram should not be used in conjunction with mechanical ventilation.</p>
<p>Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>), particularly in neonates, and an increased incidence of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>, particularly in small preterm infants. There have been rare reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see <span class="Bold"><a href="#LINK_e58d1060-465e-42a1-b290-88695bd06266">PRECAUTIONS, Pediatric Use</a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e821c5d5-c25e-441e-a554-1259d77c8ea3"></a><a name="section-6.1"></a><p></p>
<h2>In Postanesthetic Use</h2>
<ol class="LittleAlpha">
<li>Doxapram is neither an antagonist to muscle relaxant drugs nor a specific narcotic antagonist. More specific tests (eg, peripheral nerve stimulation, airway pressures, head lift, pulse oximetry, and end-tidal <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>) to assess adequacy of ventilation are recommended before administering doxapram. 
</li>
<li>Doxapram should be administered with great care and only under careful supervision to patients with hypermetabolic states such as <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>. 
</li>
<li>Since <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">narcosis</span> may recur after stimulation with doxapram, care should be taken to maintain close observation until the patient has been fully alert for Â½ to 1 hour. 
</li>
<li>In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> (see <span class="Bold"><a href="#LINK_bfa857d2-b333-4c31-9a3a-8a7f180f99b0">PRECAUTIONS, Drug Interactions</a></span>).</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_75e859cf-2868-476f-a8ce-bae4202282f8"></a><a name="section-6.2"></a><p></p>
<h2>In Drug-Induced CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are <span class="Bold"><span class="Italics">severely</span></span> depressed either due to <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d27caf7c-50ab-401e-bcb8-e958a4f10b2b"></a><a name="section-6.3"></a><p></p>
<h2>In <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span></h2>
<p class="First">Because of the associated <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">increased work of breathing</span>, do not increase the rate of infusion of doxapram in severely ill patients in an attempt to lower pCO<span class="Sub">2</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_0202fc96-00dc-4419-9c0b-e01b44884784"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_7623a325-e864-4a70-9665-4506b5da9ef8"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<ol class="LittleAlpha">
<li>An adequate airway is essential and airway protection should be considered since doxapram may stimulate <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. 
</li>
<li>Recommended dosages of doxapram should be employed and maximum total dosages should not be exceeded. In order to avoid side effects, it is advisable to use the minimum effective dosage. 
</li>
<li>Monitoring of the blood pressure, pulse rate, and deep tendon reflexes is recommended to prevent overdosage. 
</li>
<li>Vascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> or use of a single injection site over an extended period should be avoided since either may lead to <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or local <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>. 
</li>
<li>Rapid infusion may result in <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. 
</li>
<li>Lowered pCO<span class="Sub">2</span> induced by <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> produces <span class="product-label-link" type="condition" conceptid="4249605" conceptname="Spasm of cerebral arteries">cerebral vasoconstriction</span> and slowing of the cerebral circulation. This should be taken into consideration on an individual basis. In certain patients a pressor effect of doxapram on the pulmonary circulation may result in a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> of the arterial pO<span class="Sub">2</span> probably due to a worsening of ventilation perfusion-matching in the lungs despite an overall improvement in alveolar ventilation and a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in pCO<span class="Sub">2</span>. Patients should be carefully supervised taking into account available blood gas measurements. 
</li>
<li>There is a risk that doxapram will produce adverse effects (including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>) due to general central nervous system stimulation. Muscle involvement may range from <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">fasciculation</span> to <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span>. Anticonvulsants such as intravenous short-acting barbiturates, along with oxygen and resuscitative equipment should be readily available to manage overdosage manifested by excessive central nervous system stimulation. Slow administration of the drug and careful observation of the patient during administration and for some time subsequently are advisable. These precautions are to assure that the protective reflexes have been restored and to prevent possible post-<span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> or <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>. 
</li>
<li>Doxapram should be administered cautiously to patients receiving sympathomimetic or monoamine oxidase inhibiting drugs, since an additive pressor effect may occur. 
</li>
<li>Blood pressure increases are generally modest but significant increases have been noted in some patients. Because of this, doxapram is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (see <span class="Bold"><a href="#LINK_0c7e3632-c211-41d1-aa40-030c23f57c57">CONTRAINDICATIONS</a></span>). 
</li>
<li>Cardiovascular effects may include various <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>. Patients receiving doxapram should be monitored for disturbance of their cardiac rhythm. 
</li>
<li>If sudden <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> develops, doxapram should be stopped. 
</li>
<li>Doxapram should be administered with caution to patients with significantly impaired hepatic or renal function as a reduction in the rate of metabolism or excretion of metabolites may alter the response.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_29b2dd83-2a28-4961-a437-6ce49974e2df"></a><a name="section-7.2"></a><p></p>
<h2>In Postanesthetic Use</h2>
<ol class="LittleAlpha">
<li>The same consideration to pre-existing disease states should be exercised as in non-anesthetized individuals. See <span class="Bold"><a href="#LINK_0c7e3632-c211-41d1-aa40-030c23f57c57">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#LINK_b04a2a24-6d60-41fd-b801-2813cbb40852">WARNINGS</a></span> covering use in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, disturbances of respiratory mechanics including airway obstruction, CNS disorders including increased cerebrospinal fluid pressure, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and profound <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>. 
</li>
<li>See <span class="Bold"><a href="#LINK_bfa857d2-b333-4c31-9a3a-8a7f180f99b0">PRECAUTIONS, Drug Interactions</a></span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_305fc936-0113-4437-a913-1245171146c9"></a><a name="section-7.3"></a><p></p>
<h2>In <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span></h2>
<ol class="LittleAlpha">
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> seen in some patients in <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span> secondary to <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> are probably the result of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>. Doxapram should be used with caution in these patients.
</li>
<li>Arterial blood gases should be drawn prior to the initiation of doxapram infusion and oxygen administration, then at least every Â½ hour during the infusion period to prevent development of CO<span class="Sub">2</span> retention and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> in patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> with acute <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>. Doxapram administration does not diminish the need for careful monitoring of the patient or the need for supplemental oxygen in patients with <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span>. Doxapram should be stopped if the arterial blood gases deteriorate, and mechanical ventilation should be initiated.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_bfa857d2-b333-4c31-9a3a-8a7f180f99b0"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see <span class="Bold"><a href="#LINK_7623a325-e864-4a70-9665-4506b5da9ef8">PRECAUTIONS, General</a></span>).</p>
<p>In patients who have received neuromuscular blocking agents, doxapram may temporarily mask the residual effects of these drugs.</p>
<p>In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> (see <span class="Bold"><a href="#LINK_b04a2a24-6d60-41fd-b801-2813cbb40852">WARNINGS</a></span>).</p>
<p>There may be an interaction between doxapram and aminophylline and between doxapram and theophylline manifested by increased skeletal muscle activity, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_18f5d807-59d2-4367-8adb-d89da8d57f77"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenic or mutagenic studies have been performed using doxapram. Doxapram did not adversely affect the breeding performance of rats.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_e2e4ba01-e109-4992-b944-7ed50feb1455"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d10b64bf-3a8d-4a48-ab90-06f963f073cb"></a><a name="section-7.6.1"></a><p></p>
<h3>PREGNANCY CATEGORY B</h3>
<p class="First">Reproduction studies have been performed in rats at doses up to 1.6 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to doxapram. There are, however, no adequate and well-controlled studies in pregnant women. Because the animals in the reproduction studies were dosed by the IM and oral routes and animal reproduction studies, in general, are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_61faf4d5-1f7f-44e4-8891-9c5eb7d2fd21"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when doxapram hydrochloride is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_e58d1060-465e-42a1-b290-88695bd06266"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12Â years have not been established. This product contains benzyl alcohol as a preservative. Benzyl alcohol, a component of this product, has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, particularly in pediatric patients. The â€œgasping syndromeâ€?, (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages &gt;99Â mg/kg/day in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the â€œgasping syndromeâ€?, the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.</p>
<p>Premature neonates given doxapram have developed <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, glucosuria, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, increased gastric residuals, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>, <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>, erratic limb movements, excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, disturbed sleep, premature <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span> of teeth, and QT prolongation that has resulted in <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. In premature neonates with risk factors such as a previous <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, perinatal <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">asphyxia</span>, or <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">intracerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have occurred. In many instances, doxapram was administered following administration of xanthine derivatives such as caffeine, aminophylline or theophylline.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_6cfea4ee-629f-4d29-91c0-4e4e0021ed91"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions reported coincident with the administration of DOPRAM (doxapram hydrochloride, USP) include:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_070619aa-a4eb-4aa6-9e7a-e90f63d8bdbf"></a><a name="section-8.1"></a><p></p>
<h2>1. Central and Autonomic Nervous Systems</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, such as a <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling of warmth</span>, burning, or hot sensation, especially in the area of genitalia and perineum; <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, pupillary dilatation, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, involuntary movements, <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">muscle spasticity</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">muscle fasciculations</span>, increased deep tendon reflexes, <span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonus</span>, bilateral Babinski, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_239b56eb-5e56-468f-8eb8-177523198fb7"></a><a name="section-8.2"></a><p></p>
<h2>2. Respiratory</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccough</span>, and rebound <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ad8e1909-27a2-4427-b682-f8892adca711"></a><a name="section-8.3"></a><p></p>
<h2>3. Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span>, variations in heart rate, lowered T-waves, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">tightness in chest</span>. A mild to moderate increase in blood pressure is commonly noted and may be of concern in patients with severe cardiovascular diseases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a70c7ea-ade8-4af2-8e72-b2e099deb759"></a><a name="section-8.4"></a><p></p>
<h2>4. Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, desire to defecate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c6f5f606-16f0-41c2-8ffb-f67c121188dc"></a><a name="section-8.5"></a><p></p>
<h2>5. Genitourinary</h2>
<p class="First">Stimulation of urinary bladder with spontaneous voiding; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Elevation of BUN and <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_978b0819-545f-4caf-8cdc-ee85d4c514c0"></a><a name="section-8.6"></a><p></p>
<h2>6. Hemic and Lymphatic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">Hemolysis</span> with rapid infusion. A decrease in hemoglobin, hematocrit, or red blood cell count has been observed in postoperative patients. In the presence of pre-existing <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, a further decrease in WBC has been observed following anesthesia and treatment with doxapram hydrochloride.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_11d667d1-05d1-4cc3-ae61-9e2aa732c692"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3065064f-7017-47a2-9419-db66d99cfe64"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Symptoms of overdosage are extensions of the pharmacologic effects of the drug. Excessive pressor effect, such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, and enhanced deep tendon reflexes may be early signs of overdosage. Therefore, the blood pressure, pulse rate, and deep tendon reflexes should be evaluated periodically and the dosage or infusion rate adjusted accordingly.</p>
<p>Other effects may include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span> are unlikely at recommended dosages. In unanesthetized animals, the convulsant dose is 70 times greater than the respiratory stimulant dose. Intravenous LD<span class="Sub">50</span> values in the mouse and rat were approximately 75Â mg/kg and in the cat and dog were 40 to 80Â mg/kg.</p>
<p>Except for management of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> associated with acute <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, the maximum recommended dosage is 3Â GRAMS/24Â HOURS. (See <span class="Bold"><a href="#LINK_e82b2ef3-3390-46d6-a7f6-7bcb87069953">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5e61f266-3445-48e1-a71e-e73f84bdabab"></a><a name="section-9.2"></a><p></p>
<h2>Management</h2>
<p class="First">There is no specific antidote for doxapram. Management should be symptomatic. Anticonvulsants, along with oxygen and resuscitative equipment should be readily available to manage overdosage manifested by excessive central nervous system stimulation. Slow administration of the drug and careful observation of the patient during administration and for some time subsequently are advisable. These precautions are to assure that the protective reflexes have been restored and to prevent possible post-<span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> or <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>.</p>
<p>There is no evidence that doxapram is dialyzable; further, the half-life of doxapram makes it unlikely that dialysis would be appropriate in managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with this drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e82b2ef3-3390-46d6-a7f6-7bcb87069953"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">NOTE: CONTAINS BENZYL ALCOHOL (see </span><span class="Bold"><a href="#LINK_0202fc96-00dc-4419-9c0b-e01b44884784">PRECAUTIONS</a></span><span class="Bold">)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_06a17b68-894a-46a9-b84b-bf4d517a6bd7"></a><a name="section-10.1"></a><p></p>
<h2>In Postanesthetic Use</h2>
<table>
<caption><span>Table I. Dosage for postanesthetic use-I.V. and infusion.</span></caption>
<col>
<col>
<col>
<col>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Dose not to exceed 3 grams/24 hours.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center" rowspan="2">Â <span class="Bold">I.V.</span><span class="Bold"> Administration</span>
</td>
<td align="center" valign="bottom">Â <span class="Bold">Recommended Dosage<br>mg/kg</span>
</td>
<td align="center" valign="bottom">Â <span class="Bold">Maximum dose per single injection<br>mg/kg</span>
</td>
<td align="center" valign="bottom">Â <span class="Bold">Maximum total <br>dose<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>mg/kg</span>
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="bottom">Â </td>
<td class="Botrule" align="center" valign="bottom">Â </td>
<td class="Botrule" align="center" valign="bottom">Â </td>
</tr>
<tr>
<td valign="top">Â  Single Injection </td>
<td align="center">Â  0.5-1 </td>
<td align="center">Â  1.5 </td>
<td align="center">Â  1.5 </td>
</tr>
<tr>
<td valign="top">Â  Repeat Injections<br>(5 min. intervals) </td>
<td align="center">Â  0.5-1 </td>
<td align="center">Â  1.5 </td>
<td align="center">Â  2 </td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â  Infusion </td>
<td class="Botrule" align="center">Â  0.5-1 </td>
<td class="Botrule" align="center">Â  â€“ </td>
<td class="Botrule" align="center">Â  4 </td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ba9eacd7-e625-4c56-a186-65a1665abd08"></a><a name="section-10.1.1"></a><p></p>
<h3>BY I.V. INJECTION</h3>
<p class="First">(See Table I. Dosage for postanesthetic useâ€”I.V.)</p>
<p>The recommended dose for I.V. administration is 0.5 â€“ 1 mg/kg for a single injection and at 5-minute intervals. Careful observation of the patient during administration and for some time subsequently are advisable. The maximum total dosage by I.V. injection is 2 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8a4121d6-4b32-4433-bef2-1b007eb4b9bd"></a><a name="section-10.1.2"></a><p></p>
<h3>BY INFUSION</h3>
<p class="First">The solution is prepared by adding 250Â mg of doxapram (12.5Â mL) to 250Â mL of dextrose 5% or 10% in water or normal saline solution. The infusion is initiated at a rate of approximately 5Â mg/minute until a satisfactory respiratory response is observed, and maintained at a rate of 1 to 3Â mg/minute. The rate of infusion should be adjusted to sustain the desired level of respiratory stimulation with a minimum of side effects. The maximum total dosage by infusion is 4Â mg/kg, or approximately 300Â mg for the average adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9492463b-5e3f-429c-8f3b-ada0d59274e9"></a><a name="section-10.2"></a><p></p>
<h2>In the Management of Drug-Induced <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></h2>
<p class="First">(See Table II. Dosage for drug-induced <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.)</p>
<table>
<caption><span>Table II. Dosage for drug-induced <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</span></caption>
<col>
<col>
<col>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> <br>Class 0: Asleep, but can be aroused and can answer questions. <br>Class 1: <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Comatose</span>, will withdraw from painful stimuli, reflexes intact.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>Moderate <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> <br>Class 2: <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Comatose</span>, will not withdraw from painful stimuli, reflexes intact. <br>Class 3: <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Comatose</span>, reflexes absent, no <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of circulation or respiration.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td>Â </td>
<td align="center">Â <span class="Bold">METHOD ONE <br>Priming dose single/repeat I.V. Injection</span>
</td>
<td align="center">Â <span class="Bold">METHOD TWO <br>Rate of Intermittent I.V. Infusion</span>
</td>
</tr>
<tr>
<td class="Botrule">Â  Level of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> </td>
<td class="Botrule" align="center">Â <span class="Bold">mg/kg</span>
</td>
<td class="Botrule" align="center">Â <span class="Bold">mg/kg/hr</span>
</td>
</tr>
<tr>
<td>Â Mild<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td align="center">Â  1 </td>
<td align="center">Â  1-2 </td>
</tr>
<tr class="Last">
<td class="Botrule">Â Moderate<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a>
</td>
<td class="Botrule" align="center" valign="top">Â  2 </td>
<td class="Botrule" align="center" valign="top">Â  2-3 </td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_079f38bb-8d97-4e2e-bb29-62e5d8f17641"></a><a name="section-10.2.1"></a><p></p>
<h3>METHOD ONE</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7404492d-d6a9-4d52-8583-d128a52c7b08"></a><a name="section-10.2.1.1"></a><p></p>
<h4><span class="Italics">Using Single and/or Repeat Single I.V. Injections</span></h4>
<ol class="LittleAlpha">
<li>Give priming dose of 2 mg/kg body weight and repeat in 5 minutes. The priming dose for moderate <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is 2 mg/kg and the priming dose for mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is 1 mg/kg. 
</li>
<li>Repeat same dose q 1 to 2h until patient wakens. Watch for relapse into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> or development of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, since DOPRAM does not affect the metabolism of CNS-depressant drugs. 
</li>
<li>If relapse occurs, resume injections q 1 to 2h until arousal is sustained, or total maximum daily dose (3 grams) is given. After maximum dose has been given (3 grams), allow patient to sleep until 24 hours have elapsed from first injection of DOPRAM, using assisted or automatic respiration if necessary. 
</li>
<li>Repeat procedure the following day until patient breathes spontaneously and sustains desired level of consciousness, or until maximum dosage (3 grams) is given. 
</li>
<li>Repetitive doses should be administered only to patients who have shown response to the initial dose. 
</li>
<li>Failure to respond appropriately indicates the need for neurologic evaluation for a possible central nervous system source of sustained <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ff535420-897d-4298-b574-85bb69c69929"></a><a name="section-10.2.2"></a><p></p>
<h3>METHOD TWO</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46f4f431-db83-4185-a9d2-8d222e8fa208"></a><a name="section-10.2.2.1"></a><p></p>
<h4><span class="Italics">By Intermittent I.V. Infusion</span></h4>
<ol class="LittleAlpha">
<li>Give priming dose as in Method One. 
</li>
<li>If patient wakens, watch for relapse; if no response, continue general supportive treatment for 1 to 2 hours and repeat priming dose of DOPRAM. If some respiratory stimulation occurs, prepare I.V. infusion by adding 250 mg of DOPRAM (12.5 mL) to 250 mL of saline or dextrose solution. Deliver at rate of 1 to 3 mg/min (60 to 180 mL/hr) according to size of patient and depth of <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Discontinue DOPRAM if patient begins to waken or at end of 2 hours. 
</li>
<li>Continue supportive treatment for Â½ to 2 hours and repeat Step b. 
</li>
<li>Do not exceed 3 grams/day.</li>
</ol>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_85df44d4-4b58-4b32-b9d6-b1946ce0048c"></a><a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span> Associated with Acute <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">Hypercapnia</span></h2>
<ol class="LittleAlpha">
<li>One vial of doxapram (400 mg) should be mixed with 180 mL of dextrose 5% or 10% or normal saline solution (concentration of 2 mg/mL). The infusion should be started at 1 to 2 mg/minute (Â½ to 1 mL/minute); if indicated, increase to a maximum of 3 mg/minute. Arterial blood gases should be determined prior to the onset of doxapramâ€™s administration and at least every half hour during the two hours of infusion to insure against the insidious development of CO<span class="Sub">2</span>-RETENTION AND <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">ACIDOSIS</span>. Alteration of oxygen concentration or flow rate may necessitate adjustment in the rate of doxapram infusion.
</li>
<li>Predictable blood gas patterns are more readily established with a continuous infusion of doxapram. If the blood gases show evidence of deterioration, the infusion of doxapram should be discontinued.
</li>
<li>ADDITIONAL INFUSIONS BEYOND THE SINGLE MAXIMUM TWO HOUR ADMINISTRATION PERIOD ARE NOT RECOMMENDED.</li>
</ol>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_33d49671-17ee-4d25-ac36-eb487b7c13d1"></a><a name="section-10.4"></a><p></p>
<h2>Diluent Compatibility</h2>
<p class="First">Doxapram hydrochloride is compatible with 5% and 10% dextrose in water or normal saline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a6b5ed42-c231-4340-a16c-6204457009d2"></a><a name="section-10.5"></a><p></p>
<h2>Incompatibility</h2>
<p class="First">ADMIXTURE OF DOXAPRAM WITH ALKALINE SOLUTIONS SUCH AS 2.5% THIOPENTAL SODIUM, SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span>, FUROSEMIDE, OR AMINOPHYLLINE WILL RESULT IN PRECIPITATION OR GAS FORMATION.</p>
<p>Doxapram is also not compatible with ascorbic acid, cefoperazone sodium, cefotaxime sodium, cefotetan sodium, cefuroxime sodium, folic acid, dexamethasone disodium phosphate, diazepam, hydrocortisone sodium phosphate, methylprednisolone sodium, or hydrocortisone sodium succinate.</p>
<p>Admixture of doxapram and ticarcillin disodium results in an 18% loss of doxapram in 3 hours. When doxapram is mixed with minocycline hydrochloride, there is a loss of 8% of doxapram in 3Â hours and a 13% loss of doxapram in 6Â hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_aa816e46-8a9d-4a75-8949-4a043b541d85"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">DOPRAM Injection (doxapram hydrochloride injection, USP) is available in boxes of six 20 mL multiple dose vials containing 20Â mg of doxapram hydrochloride per mL with benzyl alcohol 0.9% as the preservative (NDCÂ 0641-6018-06).</p>
<p><span class="Bold">Store at Controlled Room Temperature, Between 20ËšC to 25ËšC (68ËšF to 77ËšF). See USP.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d4e7459e-42ec-460e-83ab-440bf84a063f"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or <a href="#medwatch">www.fda.gov/medwatch</a>.</p>
<p>For Product Inquiry call 1-877-845-0689.</p>
<p>Manufactured by:</p>
<div class="Figure">
<img alt="West-Ward logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb&amp;name=dopram-2.jpg"><p class="MultiMediaCaption"></p>
</div>
<p><span class="Bold">WEST-WARD<br></span>PHARMACEUTICALS<br>Eatontown, NJ 07724 USA</p>
<p>Revised November 2011</p>
<p>462-175-06</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_24a2c59f-a8fc-43f4-b8d8-ff94213c60fa"></a><a name="section-13"></a><p></p>
<h1>PACKAGE LABELING - PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Dopram Injection (doxapram hydrochloride injection, USP)<br>400 mg/20 mL (20 mg/mL)<br>20 mL Multiple Dose Vial<br>NDC 0641-6018-01</p>
<div class="Figure">
<img alt="Dopram Injection (doxapram hydrochloride injection, USP) 400 mg/20 mL (20 mg/mL) 20 mL Multiple Dose Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b8eb330a-a75b-46cb-b694-5be9327ed2eb&amp;name=dopram-3.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOPRAMÂ 		
					</strong><br><span class="contentTableReg">doxapram hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-6018</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXAPRAM HYDROCHLORIDE</strong> (DOXAPRAM) </td>
<td class="formItem">DOXAPRAM HYDROCHLORIDE</td>
<td class="formItem">20Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">9Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6018-06</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-6018-01</td>
<td class="formItem">20 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA014879</td>
<td class="formItem">06/23/1965</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>West-ward Pharmaceutical Corp.
							(946499746)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">West-ward Pharmaceutical Corp</td>
<td class="formItem"></td>
<td class="formItem">946499746</td>
<td class="formItem">ANALYSIS(0641-6018), LABEL(0641-6018), MANUFACTURE(0641-6018)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7c74602f-5167-4f3d-8912-f6016b2eb99e</div>
<div>Set id: b8eb330a-a75b-46cb-b694-5be9327ed2eb</div>
<div>Version: 1</div>
<div>Effective Time: 20111209</div>
</div>
</div>Â <div class="DistributorName">West-ward Pharmaceutical Corp.</div></p>
</body></html>
